Silva Francisco 4
4 · BioRestorative Therapies, Inc. · Filed Apr 10, 2024
Insider Transaction Report
Form 4
Silva Francisco
VP of Research and Development
Transactions
- Purchase
Common Stock
2024-04-08$1.17/sh+1,232$1,441→ 149,159 total - Purchase
Common Stock
2024-04-08$1.13/sh+476$538→ 147,927 total - Purchase
Common Stock
2024-04-09$1.25/sh+6,600$8,250→ 155,759 total
Holdings
- 25
Stock Option
Exercise: $3000.00Exp: 2028-10-29→ Common Stock (25 underlying) - 293,479
Stock Option
Exercise: $5.08Exp: 2031-03-18→ Common Stock (293,479 underlying) - 9
Stock Option
Exercise: $3000.00Exp: 2024-10-23→ Common Stock (9 underlying) - 6
Stock Option
Exercise: $3000.00Exp: 2025-09-04→ Common Stock (6 underlying) - 20
Stock Option
Exercise: $3000.00Exp: 2027-07-12→ Common Stock (20 underlying) - 12,136(indirect: By IRA)
Common Stock
- 15
Stock Option
Exercise: $3000.00Exp: 2026-06-10→ Common Stock (15 underlying) - 42,059
Stock Option
Exercise: $5.08Exp: 2031-11-04→ Common Stock (42,059 underlying) - 106,762
Stock Option
Exercise: $2.91Exp: 2033-02-17→ Common Stock (106,762 underlying) - 394,737
Stock Option
Exercise: $1.45Exp: 2034-02-13→ Common Stock (394,737 underlying)
Footnotes (4)
- [F1]The option is currently exercisable.
- [F2]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
- [F3]The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
- [F4]The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.